Wellness Franchise Opportunities

HealthcareMay, 11 2015

India to participate in first clinical study trial to treat spinal cord injury using stem cells

By involving 18 patients, India will soon become a part of a first-of-its-kind clinical trial, a collaborative study conducted in China, Norway and America, involving 240 patients for treating spinal cord injury in humans through stem-cells.

By Agencies

India will be a part of a first-of-its-kind clinical trial, for treating spinal cord injury in humans through stem-cells. India will a part of the collaborative study conducted in China, Norway and America involving 240 patients led by China-based stem cell researcher Dr Wise Young.

The pre-clinical trial of the project has already been completed in the US and also the first phase clinical trials in China involving 120 patients. The phase 2b trial on humans in India will begin with six patients, each from Bombay Hospital, Mumbai, NeuroGen Brain and Spine Institute, Mumbai and Apollo Hospital, Chennai.

The stem cells are blank cells and can transform and multiply rapidly into any type of tissue in the body. They can regenerate, repair and replace damaged body parts of a human.

As per an expert associated with the development, "Approval will be sought from the Drug Controller General of India (DCGI), following consent from the ethical committees of the Indian hospitals- Bombay Hospital, NeuroGen Brain and Spine Institute and Apollo Hospital."
As a part of the study, the stem cells derived from umbilical cord blood will be sourced from China. These cells could be stored for 25 years through cryopreservation technique.

However, since these cells are derived from outside the patient, the donor cells have to be compatible with the recipient. In fact, various cord blood banking companies store these cells.

The umbilical cord blood is the residual amount of blood left behind in the umbilical cord and placenta after the delivery of a baby. This is generally discarded as it contains appreciable amount of stem cells of different types, mainly haematopoietic progenitor cells. It is capable of regenerating the entire blood and immune system and also form new blood channels.

Once collected, processed and cryogenically stored immediately after the child’s birth, it retains its potency and could be used on demand, with negligible turnaround time.

They have been used successfully in transplants for reconstitution of bone marrow in malignant and degenerative diseases, correction of genetically transmitted haematological disorders like thalassaemias and potentially for cellular therapies and regenerative medicine.

The bone marrow, mobilised peripheral blood and umbilical cord blood are the easily accessible sources of stem cells.

Related: Healthcare start-up Lybrate raises over $10 mn from Ratan Tata & Tiger Global

Click Here to add Comment
Please add your Comment
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.


Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.

Recommended For You

Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.